Effective correction of hyperhomocysteinemia in hemodialysis patients by intravenous folinic acid and pyridoxine therapy

Kidney International

Volumn 56, Issue 6, 1999, Pages 2292-2296

  Touam, Malik ^a   Zingraff, Johanna ^a   Jungers, Paul ^a   Chadefaux Vekemans, Bernadette ^a   Drüeke, Tilman ^a   Massy, Ziad A ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Dialysis; Folic acid; Methyltetrahydrofolate; Total homocysteine

Indexed keywords

FOLINIC ACID; HOMOCYSTEINE; PYRIDOXINE; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DIET SUPPLEMENTATION; DRUG EFFECT; FEMALE; HEMODIALYSIS; HUMAN; HYPERHOMOCYSTEINEMIA; MALE; PRIORITY JOURNAL; VITAMIN DEFICIENCY;

EID: 0033460314     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1999.00792.x     Document Type: Article

References (24)

1. 1. Robinson K, Gupta A, Dennis V, Arheart K, Chaudhary D, Green R, Vigo P, Mayer A, Selhub J, Kunter M, Jacobsen DW: Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 94:2743-2748, 1996
2. 2. Bostom AG, Shemin D, Verhoef P, Nadeau MR, Jacques PF, Selhub J, Dworkin L, Rosenberg IH: Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients: A prospective study. Arterioscler Thromb Vasc Biol 17:2554-2558, 1997
3. 3. Moustapha A, Naso A, Nahlawi M, Gupta A, Arheart K, Jacobsen DW, Robinson K, Dennis V: Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 97:138-141, 1998
4. 4. Bostom AG, Shemin D, Lapane KL, Hume AL, Yoburn D, Nadeau MR, Bendich A, Selhub J, Rosenberg I: High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 49:147-152, 1996
5. 5. Janssen MJ, Van Guldener C, De Jong GM, Van Den Berg M, Stehouver CDA, Donker AJM: Folic acid treatment of hyperhomocysteinemia in dialysis patients. Miner Electrolyte Metab 22:110-114, 1996
6. 6. Van Guldener C, Janssen MJ, Lambert J, ter Wee PM, Jacobs C, Donker AJM, Stehouwer CDA: No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinemia in hemodialysis patients. Nephrol Dial Transplant 13:106-112, 1998
7. 7. Perna A, Ingrosso D, De Santo NG, Galletti P, Brunone M, Zappia V: Metabolic consequences of folate-induced reduction of hyperhomocysteinemia in uremia. J Am Soc Nephrol 8:1899-1905, 1997
8. 8. Perry J, Chanarin I: Intestinal absorption of reduced folate compounds in man. Br J Haematol 18:329-339, 1970
9. 9. Kelly GS: Folates: Supplemental forms and therapeutic applications. Altern Med Rev 3:208-220, 1998
10. 10. Jennette JC, Goldman D: Inhibition of the membrane transport of folates by anion retained in uremia. J Lab Clin Med 86:834-843, 1975
11. 11. Malinow MR: Homocysteine and arterial occlusive diseases. J Intern Med 236:603-617, 1994
12. 12. Said HM, Vaziri ND, Kariger RK, Hollander D: Intestinal absorption of 5-methyltetrahydrofolate in experimental uremia. Acta Vitaminol Enzymol 6:339-346, 1984
13. 13. Reteif FP, Heyens AP, Oosthuizen M, van Reenen OR: Aspects of folate metabolism in renal failure. Br J Hematol 36:405-415, 1977
14. 14. McGuire BW, Sia LL, Leese PT, Gutierrez ML, Stokstad EL: Pharmacokinetics of leucovorin calcium after intravenous, intramuscular, and oral administration. Clin Pharm 7:52-58, 1988
15. 15. Zittoun J, Tonelli AP, Marquet J, De Gialluly E, Hancock C, Yacobi A, Johnson JB: Pharmacokinetic comparison of leucovorin and levoleucovorin. Eur J Clin Pharmacol 44:569-573, 1993
16. 16. Chadefaux B, Coudé M, Hamet P, Aupetit J, Kamoun P: Rapid determination of total homocysteine in plasma. Clin Chem 35:2002, 1989
17. 17. Lucock M, Wild J, Smithells R, Hartley R: Biotransformation of pteroylmonoglutamic acid during absorption: Implications of Michaelis-Menten kinetics. Eur J Clin Nutr 43:631-635, 1989
18. 18. Kelly P, McPartlin J, Scott J: A combined high-performance liquid chromatographic-microbiological assay for folic acid. Anal Biochem 238:179-183, 1996
19. 19. Livant EJ, Tamura T, Johnston KE, Vaughan WH, Bergman SM, Forehand J, Walthaw J: Plasma folate conjugase activities and folate concentrations in patients receiving hemodialysis. J Nutr Biochem 5:504-508, 1994
20. 20. Longo DL, Herbert V: Radioassay for serum and red cell folate. J Clin Lab Invest 87:138-151, 1976
21. 21. Bagley P, Selhub J: A common mutation in the methylenetetrahydrofolate reductase gene is associated with an accumulation of formylated tetrahydrofolates in red blood cells. Proc Natl Acad Sci USA 95:13217-13220, 1998
22. 22. Chauveau PH, Chadefaux B, Coude M, Aupetit J, Kamoun P, Jungers P: Long-term folic acid (but not pyridoxine) supplementation lowers elevated plasma homocysteine level in chronic renal failure. Miner Electrolyte Metab 22:106-109, 1996
23. 23. Arnadottir M, Brattström L, Simonsen O, Thysell H, Hultberg B, Andersson A, Nilsson-Ehle P: The effect of high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients. Clin Nephrol 40:236-240, 1993
24. 24. Dierkes J, Domrose U, Ambrosch A, Schneede J, Guttormsen AB, Neumann KH, Luley C: Supplementation with vitamin B12 decreases homocysteine and methylmamonic acid but also serum folate in patients with end-stage renal disease. Metabolism 48:631-635, 1999